Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The primary objective of study is to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ETHY-001 in healthy volunteers and participants with Thyroid Eye Disease after single subcutaneous doses.
Epistemonikos ID: b51e3cfa8a306b0bbab247efb28a5d9e235b008e
First added on: Oct 22, 2026